BB Biotech AG (BION) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BB Biotech AG (BION) has a cash flow conversion efficiency ratio of -0.033x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-59.96 Million ≈ $-75.81 Million USD) by net assets (CHF1.84 Billion ≈ $2.33 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BB Biotech AG - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how BB Biotech AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does BB Biotech AG carry for a breakdown of total debt and financial obligations.
BB Biotech AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BB Biotech AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RBL Bank Limited
NSE:RBLBANK
|
-0.317x |
|
CREDITACCESS GRAMEEN LIMITED
NSE:CREDITACC
|
0.043x |
|
5N Plus Inc.
TO:VNP
|
0.107x |
|
Sarda Energy & Minerals Limited
NSE:SARDAEN
|
0.179x |
|
ePlus inc
NASDAQ:PLUS
|
-0.082x |
|
Wuhan PS Information Tech
SHE:300184
|
0.011x |
|
BW LPG Limited
F:BW9
|
0.094x |
|
Polibeli Group Ltd Class A Ordinary Shares
NASDAQ:PLBL
|
0.000x |
Annual Cash Flow Conversion Efficiency for BB Biotech AG (2003–2024)
The table below shows the annual cash flow conversion efficiency of BB Biotech AG from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see BB Biotech AG market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF2.29 Billion ≈ $2.89 Billion |
CHF304.56 Million ≈ $385.05 Million |
0.133x | +41.78% |
| 2023-12-31 | CHF2.32 Billion ≈ $2.94 Billion |
CHF218.28 Million ≈ $275.96 Million |
0.094x | +170.53% |
| 2022-12-31 | CHF2.69 Billion ≈ $3.40 Billion |
CHF-357.81 Million ≈ $-452.37 Million |
-0.133x | -8.23% |
| 2021-12-31 | CHF3.29 Billion ≈ $4.16 Billion |
CHF-404.81 Million ≈ $-511.79 Million |
-0.123x | -282.90% |
| 2020-12-31 | CHF3.90 Billion ≈ $4.93 Billion |
CHF262.45 Million ≈ $331.81 Million |
0.067x | +6.19% |
| 2019-12-31 | CHF3.39 Billion ≈ $4.29 Billion |
CHF215.02 Million ≈ $271.84 Million |
0.063x | +138.78% |
| 2018-12-31 | CHF2.88 Billion ≈ $3.65 Billion |
CHF-471.34 Million ≈ $-595.90 Million |
-0.163x | -184.11% |
| 2017-12-31 | CHF3.54 Billion ≈ $4.47 Billion |
CHF687.50 Million ≈ $869.19 Million |
0.194x | +172.74% |
| 2016-12-31 | CHF3.00 Billion ≈ $3.80 Billion |
CHF-802.07 Million ≈ $-1.01 Billion |
-0.267x | -262.76% |
| 2015-12-31 | CHF3.98 Billion ≈ $5.03 Billion |
CHF652.82 Million ≈ $825.34 Million |
0.164x | -61.02% |
| 2014-12-31 | CHF3.49 Billion ≈ $4.42 Billion |
CHF1.47 Billion ≈ $1.86 Billion |
0.421x | -4.28% |
| 2013-12-31 | CHF2.12 Billion ≈ $2.68 Billion |
CHF931.83 Million ≈ $1.18 Billion |
0.440x | +47.54% |
| 2012-12-31 | CHF1.23 Billion ≈ $1.56 Billion |
CHF367.83 Million ≈ $465.04 Million |
0.298x | +76.14% |
| 2011-12-31 | CHF1.00 Billion ≈ $1.27 Billion |
CHF169.52 Million ≈ $214.32 Million |
0.169x | +992.62% |
| 2010-12-31 | CHF1.23 Billion ≈ $1.56 Billion |
CHF-23.41 Million ≈ $-29.60 Million |
-0.019x | -117.13% |
| 2009-12-31 | CHF1.52 Billion ≈ $1.92 Billion |
CHF167.84 Million ≈ $212.19 Million |
0.111x | -67.30% |
| 2008-12-31 | CHF1.50 Billion ≈ $1.90 Billion |
CHF509.39 Million ≈ $644.01 Million |
0.339x | +197.58% |
| 2007-12-31 | CHF1.77 Billion ≈ $2.23 Billion |
CHF201.02 Million ≈ $254.14 Million |
0.114x | +1394.02% |
| 2006-12-31 | CHF2.25 Billion ≈ $2.85 Billion |
CHF-19.80 Million ≈ $-25.04 Million |
-0.009x | -226.35% |
| 2005-12-31 | CHF2.28 Billion ≈ $2.88 Billion |
CHF-6.14 Million ≈ $-7.76 Million |
-0.003x | -104.81% |
| 2004-12-31 | CHF1.91 Billion ≈ $2.42 Billion |
CHF107.32 Million ≈ $135.68 Million |
0.056x | +163.12% |
| 2003-12-31 | CHF1.94 Billion ≈ $2.45 Billion |
CHF-172.22 Million ≈ $-217.73 Million |
-0.089x | -- |
About BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domicile… Read more